AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Atara Biotherapeutics, Inc. Director's Dealing 2021

Jun 10, 2021

34205_dirs_2021-06-09_45fc6779-6978-4c6d-9ef0-d9fefae55841.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atara Biotherapeutics, Inc. (ATRA)
CIK: 0001604464
Period of Report: 2021-06-08

Reporting Person: DOBMEIER ERIC (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-08	Common Stock	A	11000	—	Acquired	39000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-08	Non-Qualified Stock Option (Right to Buy)	$13.8	A	17500	Acquired	2031-06-07	Common Stock (17500)	Direct

Footnotes

F1: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

F2: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.